Major Events - Meili Tianyuan Medical Health (02373) acquires 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan, aiming to capture the high-end beauty market in major cities [1] - Jinhai Medical Technology (02225) is actively preparing to participate in the 8th China International Import Expo [1] - China Biopharmaceutical (01177) has its selective MEK1/2 inhibitor TQ-B3234 included in the breakthrough therapy designation program [1] - Beijing Jiakesi plans to sell 90% of Jiakexi Health through capital increase and equity transfer agreements [1] - Green Power Environmental (01330) intends to invest in establishing a joint venture in Hong Kong to expand overseas environmental business [1] - Zhonghui Biotechnology (02627) applies for full circulation of H-shares [1] Operating Performance - Legend Holdings (03396) reports that its subsidiary, Legend New Science (003022.SZ), achieved a net profit attributable to shareholders of 232 million yuan in the first three quarters, an increase of 30.32% [1] - Mongol Mining (00975) reports total raw coal production of 3.6043 million tons from UHG and BN mines in the third quarter [1] - China Resources Power (00836) reports cumulative electricity sales of 161 million megawatt-hours from its subsidiary power plants in the first nine months, a year-on-year increase of 4.2% [1] - China Coal Energy (01898) reports coal sales of 19.66 million tons in September, a year-on-year decrease of 20.1% [1] - Air China (00753) reports a 1.2% year-on-year increase in passenger capacity input and a 5.6% year-on-year increase in passenger turnover in September [1]

Core Insights - The medical beauty sector experienced a slight increase of 0.28% on October 15, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Medical Beauty Sector Performance - Jinbo Biological (code: 920982) closed at 290.43, with a rise of 5.00% and a trading volume of 21,800 shares, totaling a transaction value of 628 million [1] - Huaxi Biological (code: 688363) closed at 54.72, up 1.30%, with a trading volume of 23,600 shares and a transaction value of 129 million [1] - Aimeike (code: 300896) closed at 175.15, down 0.19%, with a trading volume of 23,500 shares and a transaction value of 412 million [1] - *ST Meigu (code: 000615) closed at 3.52, down 3.03%, with a trading volume of 199,800 shares and a transaction value of 71.2 million [1] Fund Flow Analysis - The medical beauty sector saw a net outflow of 21.57 million from institutional investors and 5.26 million from retail investors, while individual investors contributed a net inflow of 26.84 million [1] - Huaxi Biological had a net inflow of 2.29 million from institutional investors, while it faced a net outflow of 5.18 million from retail investors [2] - *ST Meigu experienced a significant net outflow of 9.34 million from institutional investors, despite a net inflow of 4.25 million from retail investors [2] - Aimeike faced a net outflow of 14.53 million from institutional investors, while retail investors contributed a net inflow of 19.70 million [2]

Core Insights - The article highlights a shift in consumer behavior among young workers, who are now prioritizing cost-effective solutions for personal care, particularly in skincare and beauty treatments, opting for hospital dermatology services over traditional beauty salons [1][2][4][5]. Group 1: Changing Consumer Behavior - Young workers are increasingly focused on maximizing value for money, choosing to spend less while achieving better results in skincare [1]. - There is a growing trend of young individuals seeking medical solutions for common skin issues, such as eye strain and back pain, rather than resorting to expensive spa treatments [2][4]. - The perception of hospital dermatology as a legitimate and effective alternative to beauty salons is gaining traction, with many discovering that these services can be both affordable and effective [5][9]. Group 2: Hospital Dermatology Services - Hospital dermatology departments are being recognized for offering medical-grade skincare treatments, such as photorejuvenation and micro-needling, which are often more effective than those available at beauty salons [7][21]. - Patients report that treatments at hospitals, while sometimes slightly more expensive, can utilize insurance benefits, making them a financially savvy choice [5][17]. - The experience of receiving treatment in a hospital setting provides a sense of security and professionalism that many find lacking in beauty salons [15][20]. Group 3: Personal Experiences and Insights - Individuals have shared their experiences of transitioning from beauty salons to hospital dermatology, noting significant improvements in their skin health and overall satisfaction with the results [21][23]. - Many young workers are now incorporating dermatology visits into their daily routines, using lunch breaks to receive treatments, which reflects a shift in how personal care is approached [11][17]. - The article emphasizes that many skin issues may stem from emotional stress, suggesting that addressing underlying health concerns can be more beneficial than solely focusing on cosmetic treatments [25].

Market Overview - The medical beauty sector experienced a decline of 0.33% on October 14, with Huaxi Biological leading the drop [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Individual Stock Performance - Jinbo Biological (code: 920982) closed at 276.60, up 5.58% with a trading volume of 17,000 shares [1] - *ST Meigu (code: 000615) closed at 3.63, up 4.61% with a trading volume of 326,000 shares [1] - Aimeike (code: 300896) closed at 175.49, down 0.10% with a trading volume of 24,200 shares [1] - Huaxi Biological (code: 688363) closed at 54.02, down 1.15% with a trading volume of 33,100 shares [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 7.7391 million yuan from main funds, while retail funds experienced a net inflow of 1.0341 million yuan [1] - Speculative funds had a net outflow of 8.7732 million yuan [1] Detailed Capital Flow for Individual Stocks - Aimeike had a net outflow of 9.3340 million yuan, down 2.20% [2] - *ST Meigu experienced a net inflow of 1.1847 million yuan, up 1.03% [2] - Huaxi Biological had a significant net outflow of 10.6702 million yuan, down 5.90% [2]

Group 1 - The medical beauty sector experienced a decline of 1.92% on October 13, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] - Major stocks in the medical beauty sector showed mixed performance, with *ST Meigu rising by 5.15% to a closing price of 3.47, while Ai Meike fell by 2.32% to 175.66 [1] Group 2 - The net outflow of main funds in the medical beauty sector was 75.6993 million yuan, while retail investors saw a net inflow of 48.3038 million yuan [1] - Specific fund flows for major stocks indicated that Ai Meike had a net outflow of 51.1050 million yuan, representing a decrease of 10.15% [2] - Huaxi Biological and *ST Meigu also experienced significant net outflows of 15.8278 million yuan and 8.7665 million yuan, respectively [2]

Core Viewpoint - The company has signed an investment agreement to acquire a stake in Swiss aesthetic company Suisselle SA, enhancing its strategic relationship and expanding its presence in the global aesthetic market [1][2] Group 1: Investment Details - The investment in Suisselle will allow the company to permanently hold exclusive agency rights for the CELLBOOSTER product in China, strengthening long-term collaboration [1] - The partnership will leverage Suisselle's established platform in Europe to accelerate the promotion and sales of the company's self-developed aesthetic products in European and other overseas markets [1] Group 2: Strategic Expansion - The investment marks a significant step in the company's global strategy for the aesthetic business, completing its strategic layout in the core aesthetic markets of Europe and North America [2] - The company aims to continue driving high-quality aesthetic solutions through a combination of independent research and international collaboration, creating long-term sustainable value for shareholders and investors [2]

Market Overview - The medical beauty sector experienced a decline of 0.5% on October 10, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - The following stocks in the medical beauty sector showed varying performance: - *ST Meigu (000615)*: Closed at 3.30, down 0.30% with a trading volume of 64,200 shares [1] - Aimeike (300896): Closed at 179.84, down 0.32% with a trading volume of 27,000 shares [1] - Huaxi Biological (688363): Closed at 55.78, down 0.76% with a trading volume of 38,500 shares [1] - Jinbo Biological (920982): Closed at 267.48, down 1.95% with a trading volume of 9,733 shares [1] Capital Flow - The medical beauty sector saw a net inflow of 14.16 million yuan from main funds, while retail funds experienced a net outflow of 8.85 million yuan [1] - Detailed capital flow for specific stocks includes: - Aimeike (300896): Net outflow of 11.73 million yuan, down 2.40% [2] - *ST Meigu (000615)*: Net outflow of 1.17 million yuan, down 5.51% [2] - Huaxi Biological (688363): Net outflow of 3.72 million yuan, down 1.72% [2]

Core Viewpoint - The Shenzhen Municipal Financial Office issued a warning about the increasing risks of illegal fundraising activities, highlighting the deceptive nature and the various new schemes being employed by fraudsters to exploit the public and disrupt market order [1] Group 1: Types of Illegal Fundraising Cases - Case 1: "Agricultural Cloud Breeding" - A fraudulent scheme involving a "cloud breeding black pig" investment project that promised a fixed annual return of 60%, ultimately leading to the freezing of withdrawals and the closure of the app, with over 40,000 members and more than 1 billion yuan involved [2][3] - Case 2: "Medical Beauty" - A "beauty loan" scam where a beauty institution induced nearly 1,000 consumers to take out loans totaling 66.22 million yuan, resulting in a loss of 40.7 million yuan due to the company's collapse [4] - Case 3: "AI Computing Power Leasing" - A Ponzi scheme disguised as a cloud storage investment, promising returns of 15%-30% annually, but relying on new investors' funds to pay old investors [5] - Case 4: "RWA" - A scheme involving a "digital cultural tourism fund" that misused the concept of asset tokenization to lure investors into a fraudulent virtual currency scheme [6][7] - Case 5: "Fake State-Owned Enterprises" - A scam where a fake local investment company issued debt products under the guise of a city investment project, leading to average losses of over 200,000 yuan per investor [8] - Case 6: "Gold Investment" - A fraudulent "golden interest" scheme where a company falsely claimed to hold a trading license, resulting in investors losing money due to the lack of actual gold assets [9] Group 2: Characteristics of Fraudulent Activities - The fraudulent schemes often feature three main characteristics: the use of "agriculture + technology" as a marketing gimmick, strong online presence making it difficult to track funds, and multiple illegal risks including illegal fundraising and pyramid schemes [3] - The medical beauty sector has become a new hotspot for illegal fundraising, with fraudsters targeting young women and entrepreneurs by bundling illegal fundraising with beauty services [4] - High-tech concepts like AI and cloud computing are exploited by fraudsters to create false investment opportunities, promising high returns while engaging in illegal fundraising activities [5] Group 3: Regulatory Recommendations - The Shenzhen Municipal Financial Office emphasizes the importance of verifying the qualifications of financial institutions and suggests using five authoritative channels for checking the legitimacy of financial products and services [10][11]

Core Insights - The medical beauty sector experienced a slight increase of 0.18% on October 9, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Medical Beauty Sector Performance - Huaxi Biological (688363) closed at 56.21, with a rise of 1.43% and a trading volume of 40,100 shares [1] - Aimeike (300896) closed at 180.42, down 0.62% with a trading volume of 29,300 shares [1] - ST Meigu (000615) closed at 3.31, down 0.90% with a trading volume of 124,000 shares [1] - Jinbo Biological (920982) closed at 272.80, down 3.12% with a trading volume of 10,000 shares [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 44.2015 million yuan from main funds and a net outflow of 32.526 million yuan from speculative funds, while retail investors had a net inflow of 76.7274 million yuan [1] - Huaxi Biological had a main fund net inflow of 5.4613 million yuan, accounting for 2.45% of its total [2] - Aimeike experienced a significant main fund net outflow of 47.1115 million yuan, representing 8.95% of its total [2] - ST Meigu had a main fund net outflow of 2.5512 million yuan, accounting for -6.23% of its total [2]

新华社音视频部制作 记者：高菲菲 王伟 秋季出行应该做好哪些皮肤护理攻略？新华社《健康我来说》邀请北京大学第一医院整形烧伤科主任温 冰，为大家答疑解惑。 ...